Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company centered on metabolic dysfunction-associated steatohepatitis (MASH), with its lead therapy Rezdiffra (resmetirom) and a growing pipeline of liver-directed treatments. The MDGL news feed on Stock Titan aggregates company announcements and third-party coverage so readers can follow how Madrigal’s clinical, regulatory, and commercial activities evolve over time.
News about Madrigal frequently highlights new clinical data from its Phase 3 MAESTRO program, including imaging, biomarker, and quality-of-life results in patients with MASH and compensated MASH cirrhosis (F4c). The company also issues updates on outcomes from major scientific meetings such as the American Association for the Study of Liver Diseases (AASLD) Liver Meeting and presentations at healthcare investment conferences.
Investors and healthcare observers will see regular press releases on Rezdiffra’s commercial performance, including product revenue, patient and prescriber adoption, and geographic expansion following regulatory approvals in the U.S. and Europe. Madrigal also reports on licensing transactions that expand its MASH pipeline, such as global agreements for an oral GLP-1 receptor agonist and ervogastat, a DGAT-2 inhibitor intended for combination use with Rezdiffra.
Additional news items cover corporate and capital structure developments disclosed via Form 8-K filings, including financing agreements, credit facilities, and governance matters such as annual meeting results and equity inducement awards under stock plans. For users tracking MDGL stock, this page offers a centralized view of Madrigal’s latest disclosures related to Rezdiffra, its broader MASH program, and key financial and strategic milestones. Bookmark this feed to monitor new data releases, regulatory and commercial updates, and pipeline progress that may influence the company’s long-term outlook.
Madrigal Pharmaceuticals (NASDAQ: MDGL) will present secondary analyses from its Phase 2 NASH study involving MGL-3196 (resmetirom) at the Digital International Liver Congress on August 28, 2020. Dr. Rohit Loomba will discuss how MRI-PDFF reduction correlates with improvements in liver biopsy results, underscoring the drug's potential. Resmetirom is currently in Phase 3 trials, focusing on NASH patients with fibrosis stage 2-3. The results aim to demonstrate efficacy in reducing liver fat and improving cardiovascular outcomes, with a Phase 3 trial expected to enroll 900 patients.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported its Q2 2020 financial results, showing a cash balance of $384.4 million as of June 30, a decrease from $439.0 million at year-end 2019, primarily due to $54.8 million in operational costs.
Operating expenses surged to $50.3 million for Q2, up from $22.7 million in 2019. R&D expenses also rose significantly to $44.7 million, reflecting ongoing Phase 3 clinical trials. Amid challenges from the pandemic, the company is focused on completing enrollment for its MAESTRO trials and received an upgrade to the NASDAQ Global Select Market.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q1 2020 financial results, stating progress in its Phase 3 studies, MAESTRO-NASH and MAESTRO-NAFLD-1, despite COVID-19 challenges. The company announced a cash position of $408.5 million, down from $439.0 million at the end of 2019, primarily due to operational expenses of $30.5 million. R&D expenses surged to $33.4 million from $12.4 million year-over-year due to trial initiations. Notably, resmetirom showed over 60% reduction in liver fat and a 64% NASH resolution rate. Interest income decreased to $1.9 million.